Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1977-04-11
1979-02-20
Rose, Shep K.
Drug, bio-affecting and body treating compositions
Lymphokine
424 86, A61K 4502, A61K 4504, A61K 3912, A61K 3942
Patent
active
041407610
ABSTRACT:
Interferon introduced parenterally in a human host or stimulated by an inducer (PICLC) for a period of greater than 21 days results in a major decrease in all markers of infectivity, such as DNA polymerase, and such markers remain at a depressed level during the period of treatment. Where PICLC is utilized to induce interferon in the host, a serum level of 50 units per milliliter or higher is necessary for effective clinical treatment and 17 .times. 10.sup.4 - 6.0 .times. 10.sup.3 U/kg/day is an effective dose for exogenous interferon. Especially long-term treatment with exogenous interferon of greater than 21 days and up to 14 months results in clinical improvement for chronic hepatitis B virus (HBV) infection and this long-term treatment has resulted in sustained improvement even after cessation of treatment as well as resulting in a decrease in infectivity risk to others in close proximity to the infected human host. Such clinical improvement is marked by normalization of liver histology.
REFERENCES:
greenberg et al., Clinical Research 24:452A (1976).
Greenberg et al., New England J. of Medicine : 517-522, Sep. 2, 1976.
Purcell et al., The Lancet : 757-761, Oct. 9, 1976.
Desmyter et al., The Lancet : 645-647, Sep. 25, 1976.
Gerin Fractions No. 1, 1976.
Jacobs, Chem. & Eng. News : 24-27, Aug. 14, 1972.
Alter et al., New England J. Med. 295:909-919 (1976).
Okada, New England J. Med. 294:746-749 (1976).
Gerin John L.
Levy Hilton B.
Merigan Thomas C.
Purcell Robert H.
Robinson William S.
Ferris Thomas G.
Latker Norman J.
Roberts, Jr. John S.
Rose Shep K.
The United States of America as represented by the Department of
LandOfFree
Modification of hepatitis B virus infection in chronic carriers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modification of hepatitis B virus infection in chronic carriers , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modification of hepatitis B virus infection in chronic carriers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-258641